Synapse - Craig Moskowitz

Search Within

Craig Moskowitz

Results (407)

Phase II study of accelerated fractionation involved field radiotherapy (IFRT), total body irradiation (TBI), ifosfamide and continuous infusion etoposide with autologous stem cell transplantation (ASCT) in the treatment of patients with relapsed and primary refractory aggressive non-Hodgkins lymphoma (NHL)

Meeting Abstract

Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Kewalramani, T.; Malhotra, S.; Nimer, S. D.
Blood (2001)

Fulltext@MSK | Save

Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)

Meeting Abstract

O'Connor, O. A.; Kelly, W.; Wang, E. S.; Richon, V.; Moskowitz, C.; Tong, W.; Donnelly, G.; Zelenetz, A. D.; Moore, M. A. S.; Rifkind, R. A.; more...
Blood (2001)

Fulltext@MSK | Save

Clinical development of the novel epothilone BMS-247550: First of a new class of tubulin polymerization agents with promising activity against chemotherapy-refractory aggressive and mantle cell lymphoma

Meeting Abstract

O'Connor, O. A.; Spriggs, D. R.; Moskowitz, C.; Donnelly, G.; Zelenetz, A. D.; Whitaker, L.; Lebwohl, D.
Blood (2001)

Fulltext@MSK | Save

Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)

Meeting Abstract

Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; more...
Blood (2001)

Fulltext@MSK | Save

Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: Who benefits?

Journal Article

Kewalramani, T.; Moskowitz, C. H.
Current Oncology Reports (2001)

Fulltext@MSK | Save

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma

Journal Article

Cohen, B. J.; Moskowitz, C.; Straus, D.; Noy, A.; Hedrick, E.; Zelenetz, A.
Leukemia and Lymphoma (2001)

Fulltext@MSK | Save

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model

Journal Article

Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Trippett, T.; Hedrick, E. E.; Filippa, D. A.; Louie, D.; Gonzales, M.; Walits, J.; Coady-Lyons, N.; more...
Blood (2001)

Fulltext@MSK | Save

The outcome of patients with primary refractory Hodgkin's disease (HD) treated with high dose chemoradiotherapy and ASCT

Meeting Abstract

Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hedrick, E. E.; Gonzalez, M.; Yahalom, J.
Blood (2000)

Fulltext@MSK | Save

Outcome of adult patients (pts) with chemosensitive (CS) relapsed or primary refractory Hodgkin's disease (HD) or aggressive NHL (NHL) after failure of autologous transplantation (ASCT)

Meeting Abstract

Kewalramani, T.; Hedrick, E. E.; Malhotra, S.; Qin, J.; Yahalom, J.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
Blood (2000)

Fulltext@MSK | Save

Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma in the post-transplant setting

Meeting Abstract

Pan, D.; Moskowitz, C. H.; Zelenetz, A. D.; Teruya-Feldstein, J.; Portlock, C. S.
Blood (2000)

Fulltext@MSK | Save